Explore

Rapid Read Rapid Read
CRISPR Variant ThermoCas9 Offers Precision in Targeting Tumor DNA

CRISPR Variant ThermoCas9 Offers Precision in Targeting Tumor DNA

A team of researchers from Wageningen University & Research and Van Andel Institute has introduced ThermoCas9, a CRISPR variant that precisely targets tumor DNA by recognizing methylation patterns. This breakthrough allows for the selective cleavage of cancerous DNA while leaving healthy cells intact. The study highlights ThermoCas9's ability to differentiate between methylated and unmethylated DNA, providing a new avenue for cancer treatment that minimizes harm to normal tissue.
Rapid Read Rapid Read
Researchers Discover Method to Enhance Immune System's Cancer-Fighting Abilities

Researchers Discover Method to Enhance Immune System's Cancer-Fighting Abilities

A team of researchers from Hebrew University, Philipps University of Marburg, and the University of Texas MD Anderson Cancer Center have discovered a method to enhance the immune system's ability to fight cancer. By blocking a protein known as Ant2, they were able to alter how T cells produce and use energy, effectively rewiring their internal power supply. This transformation makes T cells more active and better equipped to destroy tumors. The study, published in Nature Communications, highlights the potential for new cancer treatment strategies that strengthen the body's natural defenses.
Rapid Read Rapid Read
Dutch Study Highlights Benefits of Off-Label Targeted Cancer Therapies for Patients

Dutch Study Highlights Benefits of Off-Label Targeted Cancer Therapies for Patients

A Dutch study has revealed that off-label targeted cancer therapies can significantly benefit patients, as demonstrated in the Dutch multicenter DRUP trial. This trial, which included over 1600 patients, aimed to expand the use of existing drugs beyond their approved indications to provide more personalized treatment options. The results, published in Nature, show that about one-third of the participants responded positively to the treatment or maintained stable disease for at least four months. The trial also identified 67 exceptional responders who showed complete response or remained progression-free for at least two years. The study underscores the potential of these targeted drugs to deliver substantial benefits, even for heavily pretreated, difficult-to-treat, or rare cancers.
Trendline Trendline
Natera Reports Positive Interim Analysis from Allogene's ALPHA3 Trial in Large B-Cell Lymphoma

Natera Reports Positive Interim Analysis from Allogene's ALPHA3 Trial in Large B-Cell Lymphoma

Natera Reports Positive Interim Analysis from Allogene's ALPHA3 Trial in Large B-Cell Lymphoma
Rapid Read Rapid Read
University of Texas Researchers Develop Miniature CRISPR for Enhanced Gene Editing in Human Cells

University of Texas Researchers Develop Miniature CRISPR for Enhanced Gene Editing in Human Cells

Researchers at the University of Texas at Austin have engineered a compact version of the CRISPR-Cas12f nuclease, which shows promise for efficient gene editing in human cells. This development addresses a significant challenge in gene therapy: the large size of traditional CRISPR nucleases, which limits their delivery via adeno-associated virus (AAV) vectors. The newly developed Cas12f variant, named Al3Cas12f, is approximately one-third the size of the commonly used Cas9 enzyme. Despite its smaller size, Al3Cas12f demonstrated robust activity, achieving over 50% editing efficiency at numerous genomic sites and exceeding 90% at several targets. The research, published in Nature Structural & Molecular Biology, highlights the potential of this miniature enzyme to overcome current limitations in in vivo gene therapy applications.
Trendline Trendline
4D Path and Daiichi Sankyo Collaborate on AI-Driven Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI-Driven Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI-Driven Biomarkers for Cancer Treatment
Trendline Trendline
4D Path and Daiichi Sankyo Collaborate on AI Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI Biomarkers for Cancer Treatment
Trendline Trendline
Novigenix AI Presents Breakthrough in Immuno-Pharmacodynamics at AACR 2026

Novigenix AI Presents Breakthrough in Immuno-Pharmacodynamics at AACR 2026

Novigenix AI Presents Breakthrough in Immuno-Pharmacodynamics at AACR 2026
Rapid Read Rapid Read
AI Tool Developed to Optimize Bowel Cancer Treatment and Reduce Unnecessary Side Effects

AI Tool Developed to Optimize Bowel Cancer Treatment and Reduce Unnecessary Side Effects

Scientists from the Institute of Cancer Research in London and the RCSI University of Medicine and Health Sciences in Dublin have developed an AI tool called PhenMap. This tool is designed to identify colorectal cancer (CRC) patients who are most likely to benefit from the drug bevacizumab, which has recently been approved for NHS use in treating metastatic CRC. The AI analyzes genetic data and other clinical information to score patients based on their likelihood of benefiting from the drug, which is known to cause serious side effects in some patients. The research, published in Scientific Reports, aims to improve treatment outcomes and reduce unnecessary side effects by targeting the drug to patients who will benefit the most.
Rapid Read Rapid Read
Biofield Therapy Shows Promise in Slowing Pancreatic Cancer Progression

Biofield Therapy Shows Promise in Slowing Pancreatic Cancer Progression

A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center has found that biofield therapy (BT), a non-invasive treatment, can significantly slow the growth and spread of pancreatic cancer. Funded by the Emerald Gate Charitable Trust, the study demonstrated that BT reduced cancer cell proliferation and metastasis, particularly to the liver, by more than 50% in mouse models. The research, published in Cancer Medicine, highlights BT's potential as a complementary treatment for pancreatic cancer, one of the most lethal and treatment-resistant cancers. The study also noted changes in mitochondrial structure and cell membrane potential, along with the downregulation of cancer-related genes. The findings suggest a real biological impact from BT, warranting further investigation into its mechanisms and potential role in cancer care.
Rapid Read Rapid Read
3D Bioprinting and Photoacoustic Microscopy Enhance Cancer Drug Testing

3D Bioprinting and Photoacoustic Microscopy Enhance Cancer Drug Testing

Recent advancements in precision medicine have been highlighted through the integration of 3D bioprinting and photoacoustic microscopy (PAM) to evaluate anti-cancer drug efficacy. This innovative approach involves creating bioprinted tumor-vessel models that mimic the human tumor microenvironment. The study utilizes a custom-made high-resolution PAM system to investigate the effects of anti-cancer drugs on these models. By employing a pulsed laser for excitation, the system provides enhanced imaging depth and resolution, allowing for detailed observation of angiogenic responses and drug effects. The research demonstrates that this platform can effectively simulate tumor-induced angiogenesis and assess the impact of drugs like temozolomide and sunitinib, both individually and in combination, on vascular growth and tumor progression.
Rapid Read Rapid Read
Oregon State University Researchers Develop Promising Lung Cancer Treatment Using Lipid Nanoparticles

Oregon State University Researchers Develop Promising Lung Cancer Treatment Using Lipid Nanoparticles

Researchers at Oregon State University have developed a novel approach to address two major challenges associated with lung cancer: tumor growth and severe muscle loss. Their study, published in the Journal of Controlled Release, explores the use of lipid nanoparticles to deliver genetic material directly to cancer cells in the lungs. These nanoparticles are engineered to carry follistatin messenger RNA, which instructs cells to produce follistatin, a protein that slows tumor progression and supports muscle growth. The lipid nanoparticles are administered through the bloodstream and are directed to lung cancer tumors by binding with vitronectin, a protein found in blood serum. This method has shown a 2.5-fold greater reduction in tumor burden compared to conventional lipid nanoparticles, which tend to accumulate in the liver.